James L. Gulley, MD, PhD of National Cancer Institute at the National Institutes of Health discusses promising approaches for looking at tumor microenvironment. He mentions a study that showed patients who received standard of care therapy plus immunotherapy had a better response rate than those who only received standard of care. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.
TOX and the Tumor Microenvironment in Immunotherapy
